Euroapi

Euroapi, a French pharmaceutical preparation manufacturer, reported total Scope 1, 2, and 3 emissions of approximately 823.9 million kg CO2e in 2023. This included 70.49 million kg CO2e from Scope 1 emissions, approximately 37 million kg CO2e from market-based Scope 2 emissions, and approximately 716.5 million kg CO2e from Scope 3 emissions. Key contributors to Scope 3 emissions were purchased goods and services (about 497.4 million kg CO2e), processing of sold products (about 95.36 million kg CO2e), and use of sold products (about 95.36 million kg CO2e).

Looking ahead, Euroapi has set ambitious near-term and long-term climate commitments. The company aims to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2022 as a baseline year. Additionally, Euroapi is committed to reducing its absolute Scope 3 emissions by 25% within the same timeframe, covering categories such as purchased goods and services, capital goods, and upstream transportation and distribution. These near-term targets are validated by the Science Based Targets initiative (SBTi) as consistent with a 1.5°C warming scenario.

For the long term, Euroapi has a net-zero carbon emissions target by 2050, aiming for a 90% reduction in Scope 1, 2, and 3 emissions compared to 2022, with the remaining 10% to be compensated.

In 2022, Euroapi's total emissions were approximately 809.7 million kg CO2e, comprising 73.32 million kg CO2e from Scope 1, approximately 37.54 million kg CO2e from market-based Scope 2, and approximately 698.8 million kg CO2e from Scope 3. In 2021, the company's total emissions were approximately 746.39 million kg CO2e, with Scope 1 at 73.58 million kg CO2e, Scope 2 at 27.37 million kg CO2e, and Scope 3 at 645.43 million kg CO2e. For 2020, Euroapi reported Scope 1 emissions of 74.04 million kg CO2e and Scope 2 emissions of 40.00 million kg CO2e, for a combined total of 114.05 million kg CO2e. Scope 3 data was not disclosed for 2020.